Glucagon-Like Peptide-1 Promotes Islet Cell Growth and Inhibits Apoptosis in Zucker Diabetic Rats
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
A constant remodeling of islet cell mass mediated by proliferative and apoptotic stimuli ensures a dynamic response to a changing demand for insulin. In this study, we investigated the effect of glucagon-like peptide-1 (GLP-1) in Zucker diabetic rats, an animal model in which the onset of diabetes occurs when the proliferative potential and the rate of β-cell apoptosis no longer compensate for the increased demand for insulin. We subjected diabetic rats to a 2-d infusion of GLP-1 and tested their response to an ip glucose tolerance test. GLP-1 produced a significant increase of insulin secretion, which was paralleled by a decrease in plasma glucose levels (P < 0.001 and P < 0.01, respectively). Four days after the removal of the infusion pumps, rats were killed and the pancreas harvested to study the mechanism by which GLP-1 ameliorated glucose tolerance. Ex vivo immunostaining with the marker of cell proliferation, Ki-67, showed that the metabolic changes observed in rats treated with GLP-1 were associated with an increase in cell proliferation of the endocrine and exocrine component of the pancreas. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling staining, a marker of cellular apoptosis, indicated a reduction of apoptotic cells within the islet as well in the exocrine pancreas in GLP-1-treated rats. Double immunostaining for the apoptotic marker caspase-3 and for insulin showed a significant reduction of caspase-3 expression and an increase in insulin content in GLP-1-treated animals. Finally, staining of pancreatic sections with the nuclear dye 4,6-Diaminidino-2-phenyl-dihydrochloride demonstrated a marked reduction of fragmented nuclei in the islet cells of rats treated with GLP-1. Our findings provide evidence that the beneficial effects of GLP-1 in Zucker diabetic rats is mediated by an increase in islet cell proliferation and a decrease of cellular apoptosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies to date that have reported an increase in β-cell mass with glucagon-like peptide 1 (GLP-1)-1 based therapies were undertaken in young rodents (17–21).”
From Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice (2009) · cites this paper as [17]
Citations
Cites
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Pick, A., Clark, J., Kubstrup, C., Levisetti, M., Pugh, W., Bonner-Weir, S., & Polonsky, K. S. (1998) · Diabetes · doi:10.2337/diabetes.47.3.358 · Cited by 551
FEHMANN, H.-C., GÖKE, R., & GÖKE, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 528
Perfetti, R. (2000) · Endocrinology · doi:10.1210/en.141.12.4600 · Cited by 442
Self-citationApoptosis Participates in the Remodeling of the Endocrine Pancreas in the Neonatal Rat
Scaglia, L. (1997) · Endocrinology · doi:10.1210/en.138.4.1736 · Cited by 418
β-Cell Mass Dynamics in Zucker Diabetic Fatty Rats
Finegood, D. T., McArthur, M. D., Kojwang, D., Thomas, M. J., Topp, B. G., Leonard, T., & Buckingham, R. E. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1021 · Cited by 374
Research works printed but not linked: 2
- Nauck, 1993, Normalization of fasting hyperglycemia by exogenous glucagon-like peptide-1 [7–36 amide] in type 2 (non-insulin dependent) diabetic patients, Diabetologia, 36, 741, 10.1007/BF00401145 · DOI · Paper page
- Weibel, 1978, Stereologic methods. In: Practical methods for biologic morphometry, London: Academic Press; vol, 1, 101
Cited by
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
“Not only does it stimulate beta-cell proliferation (57, 66, 271, 333), it also enhances the differentiation of new beta cells from progenitor cells in the pancreatic duct epithelium (343).”
BackgroundThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“It has also been shown to protect cells from apoptosis (Farilla et al., 2002) and to stimulate -cell proliferation by upregulation of the -cell transcription factor pancreatic duodenal homeobox-1 protein (PDX-1) (Perfetti et al.”
BackgroundInfluentialGIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664
Self-citationVillhauer, E. B., Brinkman, J. A., Naderi, G. B., Burkey, B. F., Dunning, B. E., Prasad, K., Mangold, B. L., Russell, M. E., & Hughes, T. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030091l · Cited by 613
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
“Reduced islet apoptosis has been observed in GLP-1–treated Zucker diabetic rats (83) and in exendin-4–treated mice after streptozotocin-induced -cell injury (70).”
BackgroundBrubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 540
“More recent studies have demonstrated that GLP-1 administration also inhibits -cell apoptosis in both rats and mice (Table 2) (20, 34, 44).”
BackgroundInfluentialAhrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
“In view of the potential disease-modifying effects of the incretins (8,9), we further hypothesized that the efficacy of LAF237 would be maintained with long-term treatment.”
BackgroundGlucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
Drucker, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0306 · Cited by 483
“A 2-d continuous infusion of recombinant GLP-1 was associated with a marked increase in islet size and -cell mass, formation of new islet-like clusters, and extraislet insulin-positive cells (78).”
BackgroundMu, J., Woods, J., Zhou, Y.-P., Roy, R. S., Li, Z., Zycband, E., Feng, Y., Zhu, L., Li, C., Howard, A. D., et al. (2006) · Diabetes · doi:10.2337/db05-1602 · Cited by 449
“Measurement of islet cell mass was performed using modifications of previously described methodologies (9,12,29,30).”
MethodYusta, B., Baggio, L. L., Estall, J. L., Koehler, J. A., Holland, D. P., Li, H., Pipeleers, D., Ling, Z., & Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.001 · Cited by 446
Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394
“It has various beneficial effects on pancreatic beta cells, such as enhancement of glucose-dependent insulin secretion [18], acceleration of beta cell proliferation and inhibition of beta cell apoptosis [19].”
BackgroundGoldfine, A. B., Mun, E. C., Devine, E., Bernier, R., Baz-Hecht, M., Jones, D. B., Schneider, B. E., Holst, J. J., & Patti, M. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0918 · Cited by 377
“islet hyperplasia, as observed in rodents (25, 31), it is important”
BackgroundMari, A., Sallas, W. M., He, Y. L., Watson, C., Ligueros-Saylan, M., Dunning, B. E., Deacon, C. F., Holst, J. J., & Foley, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2460 · Cited by 361
“Moreover, animal studies suggest that chronic exposure to GLP-1 may increase -cell mass by promoting growth and differentiation and inhibiting apoptosis (11).”
BackgroundLong-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350
Młynarska, E., Czarnik, W., Dzieża, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031094 · Cited by 328
“…other tissues and organs, including the stomach by delaying gastric emptying, the heart by exerting cardioprotective effects, and adipose tissue and skeletal muscle by improving glucose uptake, and it also acts centrally on neurons in the hypothalamus, inducing a feeling of satiety [99–101].”
Glucagon-like peptide-1 prevents beta cell glucolipotoxicity
Joly, E., Prentki, M., Buteau, J., El-Assaad, W., Rhodes, C. J., & Rosenberg, L. (2004) · Diabetologia · doi:10.1007/s00125-004-1379-6 · Cited by 337
“Moreover, this gluco-incretin hormone increases islet mass in mouse pancreas in vivo [31, 38] and causes in vitro beta cell proliferation via transactivation of the epidermal growth factor receptor and subsequent activation of the phosphatidylinositol-3 kinase (PI-3K) and protein kinase C-ζ (PKC-ζ) signalling pathway…”
BackgroundAge-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice
Tschen, S.-I., Dhawan, S., Gurlo, T., & Bhushan, A. (2009) · Diabetes · doi:10.2337/db08-1651 · Cited by 331
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
“[54] Farilla L, Hui H, Bertolotto C, et al.”
BackgroundInsulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P.-O., Bezard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 309
“GLP-1 reduces cell death in islets b-cells, fibroblasts and neurons (Farilla et al., 2002; Li et al., 2005; Li et al., 2003; Perry et al., 2002a; Perry et al., 2002b).”
Hui, H., Nourparvar, A., Zhao, X., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2002-220897 · Cited by 307
“Prior observations from our laboratory have shown that GLP-1 reduced the number of apoptotic cells in the pancreas of Zucker diabetic rats (12).”
BackgroundSelf-citationGlucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
Bensellam, M., Laybutt, D. R., & Jonas, J.-C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.003 · Cited by 284
“…individuals in vitro (Lupi et al., 2008) - Stimulation of -cell proliferation and neogenesis and restoration of -cell mass in animal models of T2D (Farilla et al., 2002; Mu et al., 2006; Mu et al., 2009; Perfetti et al., 2000; Xu et al., 1999) - Improvement of glycemic control and -cell…”
BackgroundDrucker, D. J. (2003) · Endocrinology · doi:10.1210/en.2003-1147 · Cited by 274
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Upregulation of insulin receptor substrate-2 in pancreatic β cells prevents diabetes
Hennige, A. M., Burks, D. J., Ozcan, U., Kulkarni, R. N., Ye, J., Park, S., Schubert, M., Fisher, T. L., Dow, M. A., Leshan, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18581 · Cited by 262
Neonatal Exendin-4 Prevents the Development of Diabetes in the Intrauterine Growth Retarded Rat
Stoffers, D. A., Desai, B. M., DeLeon, D. D., & Simmons, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.734 · Cited by 261
“Recent studies have demonstrated that Ex-4 exerts anti-apoptotic actions on the -cell in various animal models of diabetes (24,44,45).”
BackgroundAtypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences
Carli, M., Kolachalam, S., Longoni, B., Pintaudi, A., Baldini, M., Aringhieri, S., Fasciani, I., Annibale, P., Maggio, R., & Scarselli, M. (2021) · Pharmaceuticals · doi:10.3390/ph14030238 · Cited by 250
“In addition, metformin seems to have cytoprotective properties by stimulating proliferation of pancreatic β-cells and reducing cellular apoptosis [152].”
BackgroundShirakawa, J., Fujii, H., Ohnuma, K., Sato, K., Ito, Y., Kaji, M., Sakamoto, E., Koganei, M., Sasaki, H., Nagashima, Y., et al. (2011) · Diabetes · doi:10.2337/db10-1338 · Cited by 246
Kim, S.-J., Winter, K., Nian, C., Tsuneoka, M., Koda, Y., & McIntosh, C. H. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500540200 · Cited by 241
Effect of protein, fat, carbohydrate and fibre on gastrointestinal peptide release in humans
Karhunen, L. J., Juvonen, K. R., Huotari, A., Purhonen, A. K., & Herzig, K. H. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2007.10.008 · Cited by 233
“insulin release, inhibits glucagon secretion, and increases pancreatic ß-cell growth [72,95,96].”
Liu, J.-L., Coschigano, K. T., Robertson, K., Lipsett, M., Guo, Y., Kopchick, J. J., Kumar, U., & Liu, Y. L. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00423.2003 · Cited by 218
“It has been used as a marker for cell proliferation of solid tumors, some hematological malignancies, and pancreatic islets (12, 14, 32).”
BackgroundRaun, K., von Voss, P., Gotfredsen, C. F., Golozoubova, V., Rolin, B., & Knudsen, L. B. (2007) · Diabetes · doi:10.2337/db06-0565 · Cited by 207
Ahrén, B. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.07.005 · Cited by 204
Sturis, J., Gotfredsen, C. F., Rømer, J., Rolin, B., Ribel, U., Brand, C. L., Wilken, M., Wassermann, K., Deacon, C. F., Carr, R. D., et al. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705397 · Cited by 202
“…and neogenesis (Buteau et al., 1999; Edvell & Lindström, 1999; Xu et al., 1999; Perfetti et al., 2000; Moldrup et al., 2001; Farilla et al., 2002; Rolin et al., 2002), and some studies indicate that it also inhibits b-cell apoptosis (Bregenholt et al., 2001; Farilla et al., 2002; Li et al., 2003).”
BackgroundMethodInfluentialAnti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
“However, the native hormone demonstrates a very short half-life measured in minutes when administered to humans by i.v. infusion or s.c. injection (Hui et al., 2002).”
BackgroundThe L-cell in nutritional sensing and the regulation of appetite
Spreckley, E. (2015) · Frontiers in Nutrition · doi:10.3389/fnut.2015.00023 · Cited by 198
“In addition to acute effects, GLP-1 exhibits trophic effects on β-cells (62–65); a 2-day infusion of GLP-1 increased markers of proliferation, and decreased markers of apoptosis in the pancreas of Zucker diabetic rats (Figure 3) (66).”
BackgroundFerreira, L., Teixeira-de-Lemos, E., Pinto, F., Parada, B., Mega, C., Vala, H., Pinto, R., Garrido, P., Sereno, J., Fernandes, R., et al. (2010) · Mediators of Inflammation · doi:10.1155/2010/592760 · Cited by 193
Yabe, D., & Seino, Y. (2011) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2011.07.010 · Cited by 188
“The anti-apoptotic function of GLP-1 on pancreatic b cells was suggested by studies of pancreas of exendin-4-treated db/db mice or GLP-1-infused VDF rats, which showed an increase in b cell mass and a decrease in apoptotic b cells (Farilla et al., 2002; Wang and Brubaker, 2002).”
BackgroundZhu, H., Zhang, Y., Shi, Z., Lu, D., Li, T., Ding, Y., Ruan, Y., & Xu, A. (2016) · Scientific Reports · doi:10.1038/srep26859 · Cited by 183
McLaughlin, T., Peck, M., Holst, J., & Deacon, C. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1628 · Cited by 183
Poornima, I., Brown, S. B., Bhashyam, S., Parikh, P., Bolukoglu, H., & Shannon, R. P. (2008) · Circulation: Heart Failure · doi:10.1161/circheartfailure.108.766402 · Cited by 182
“The plasma concentration of total GLP-1, including both the (7-36) and (9-36) amides, was determined in plasma collected in ice-cooled tubes containing EDTA and a dipeptidyl peptidase-4 (DPP-4) inhibitor using an antibody directed against the carboxy-terminal portion of the peptides (Linco Research).”
BackgroundMethodInfluentialTranscription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass
Buteau, J., Spatz, M. L., & Accili, D. (2006) · Diabetes · doi:10.2337/db05-0825 · Cited by 178
“In experimental animal models, GLP-1 increases islet mass (10,11).”
BackgroundKendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.015 · Cited by 176
“GLP-1, exenatide, and liraglutide have been reported to exert beneficial effects on β-cell function (insulin secretion) and (in animal studies) β-cell mass—perhaps by prevention of cell loss through apoptosis (cell death) and by promotion of β-cell growth [89-92].”
BackgroundChapter 15 Glucose‐Dependent Insulinotropic Polypeptide (Gastric Inhibitory Polypeptide; GIP)
McIntosh, C. H. S., Widenmaier, S., & Kim, S. (2009) · Vitamins & Hormones · doi:10.1016/s0083-6729(08)00615-8 · Cited by 171
The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro
Bregenholt, S., Møldrup, A., Blume, N., Karlsen, A. E., Friedrichsen, B. N., Tornhave, D., Knudsen, L. B., & Petersen, J. S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.013 · Cited by 170
The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent
Furman, B. L. (2012) · Toxicon · doi:10.1016/j.toxicon.2010.12.016 · Cited by 166
The chemistry and biological activity of heterocycle-fused quinolinone derivatives: A review
Shiro, T., Fukaya, T., & Tobe, M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.12.004 · Cited by 166
Mulherin, A. J., Oh, A. H., Kim, H., Grieco, A., Lauffer, L. M., & Brubaker, P. L. (2011) · Endocrinology · doi:10.1210/en.2011-1485 · Cited by 161
Shimoda, M., Kanda, Y., Hamamoto, S., Tawaramoto, K., Hashiramoto, M., Matsuki, M., & Kaku, K. (2011) · Diabetologia · doi:10.1007/s00125-011-2069-9 · Cited by 161
“To investigate cell apoptosis, a TUNEL assay was performed using a colorimetric apoptotic detection system (DeadEnd; Promega, Madison, WI, USA), as described previously [31].”
MethodSachdeva, M. M., & Stoffers, D. A. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0400 · Cited by 158
GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival
Buteau, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73398-6 · Cited by 158
Cure of Overt Diabetes in NOD Mice by Transient Treatment With Anti-Lymphocyte Serum and Exendin-4
Ogawa, N., List, J. F., Habener, J. F., & Maki, T. (2004) · Diabetes · doi:10.2337/diabetes.53.7.1700 · Cited by 156
Neuroprotective properties of GLP-1: theoretical and practical applications
Holst, J. J., Burcelin, R., & Nathanson, E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.549466 · Cited by 150
Therapeutic Approaches to Preserve Islet Mass in Type 2 Diabetes
Baggio, L. L., & Drucker, D. J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.110104.115624 · Cited by 149
“The antiapoptotic effects of GLP-1R agonists are associated with reductions in the levels of proapoptotic proteins such as active caspase 3 and poly-ADP-ribose polymerase (PARP) cleavage, as well as upregulation of prosurvival factors including Bcl-2, Bcl-xL, and inhibitor of apoptosis protein-2 (IAP-2) (37, 39, 47, 4…”
Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review
Bodnaruc, A. M., Prud’homme, D., Blanchet, R., & Giroux, I. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0153-3 · Cited by 139
Kim, S.-J., Nian, C., Widenmaier, S., & McIntosh, C. H. S. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00325-07 · Cited by 136
“GLP-1 (4, 12, 15, 16, 25, 55), have also been shown to involve”
BackgroundRetnakaran, R., Kramer, C. K., Choi, H., Swaminathan, B., & Zinman, B. (2014) · Diabetes Care · doi:10.2337/dc14-0893 · Cited by 136
“Coupled with preclinical data suggesting that GLP-1 may increase b-cell mass in animal models (14,15), these properties have fueled considerable interest in the possibility that GLP-1 agonists can preserve b-cell function in patients (13,16).”
Mu, J., Petrov, A., Eiermann, G. J., Woods, J. W., Zhou, Y.-P., Li, Z., Zycband, E., Feng, Y., Zhu, L., Roy, R. S., et al. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.027 · Cited by 148
Growth factors and beta cell replication
Vasavada, R. C., Gonzalez-Pertusa, J. A., Fujinaka, Y., Fiaschi-Taesch, N., Cozar-Castellano, I., & Garcia-Ocaña, A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.08.003 · Cited by 133
Kaji, K., Yoshiji, H., Ikenaka, Y., Noguchi, R., Aihara, Y., Douhara, A., Moriya, K., Kawaratani, H., Shirai, Y., Yoshii, J., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0783-4 · Cited by 139
Survival of encapsulated islets: More than a membrane story
Barkai, U., Rotem, A., & de Vos, P. (2016) · World Journal of Transplantation · doi:10.5500/wjt.v6.i1.69 · Cited by 131
Holz, G., & Chepurny, O. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456648 · Cited by 131
Bi-directional drug-microbiome interactions of anti-diabetics
Whang, A., Nagpal, R., & Yadav, H. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.046 · Cited by 136
Montanya, E., & Sesti, G. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.11.034 · Cited by 126
Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
Boer, G. A., & Holst, J. J. (2020) · Biology · doi:10.3390/biology9120473 · Cited by 155
“Besides the potentiation of glucose-induced insulin secretion, both incretins have shown to exert proliferative and anti-apoptotic effects on the β-cells [84,85].”
BackgroundKwon, G., Pappan, K. L., Marshall, C. A., Schaffer, J. E., & McDaniel, M. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310330200 · Cited by 117
GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts
Xu, G., Kaneto, H., Lopez-Avalos, M. D., Weir, G. C., & Bonner-Weir, S. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.11.007 · Cited by 115
The effects of glucagon‐like peptide‐1 on the beta cell
Vilsbøll, T. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01073.x · Cited by 115
The glucagon-like peptides: a double-edged therapeutic sword?
Perry, T., & Greig, N. H. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00160-3 · Cited by 122
Regeneration of the pancreatic β cell
Trucco, M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523935 · Cited by 112
“They may, for example, secrete factors such as glucagon-like peptides, which are useful in order to sustain an efficient regenerative process (27, 37, 38).”
The Glucagon‐Like Peptides: Pleiotropic Regulators of Nutrient Homeostasis
BRUBAKER, P. L. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1317.006 · Cited by 111
Parkes, D. G., Mace, K. F., & Trautmann, M. E. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.741580 · Cited by 108
“In nonclinical models, pharmacological dosing with GLP-1 is associated with pancreatic islet neogenesis, b-cell proliferation, and increased b-cell mass [20-23].”
BackgroundTargeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Salehi, M., Aulinger, B. A., & D'Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 109
Gonzalez, R., Reingold, B. K., Gao, X., Gaidhu, M. P., Tsushima, R. G., & Unniappan, S. (2011) · Journal of Endocrinology · doi:10.1530/joe-10-0492 · Cited by 125
“Several other insulinotropic endocrine factors including GLP-1 also have important local roles in islet www.endocrinology-journals.org Downloaded from Bioscientifica.com at 11/05/2018 10:03:55PM via free access growth, proliferation, and survival (Perfetti et al. 2000, Farilla et al. 2002).”
BackgroundGiaccari, A., Sorice, G. P., & Muscogiuri, G. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.03.018 · Cited by 121
“More recently drug companies introduced injectable GLP 1 analogues and oral inhibitors of DPP IV, the key enzyme in GLP 1 catabolism, which are able to induce beta cell secretion with an incretin mimetic mechanism [103], while inhibiting glucagon secretion and having a trophic effect on beta cell mass [104], at least…”
Role of caspases in the regulation of apoptotic pancreatic islet beta‐cells death
Hui, H., Dotta, F., Mario, U. D., & Perfetti, R. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20021 · Cited by 104
“In ZDF rats, the rate of beta-cell proliferation or neogenesis is not reduced and hyperglycemia is detected when the expansion of beta-cells mass is no longer capable of compensating for the degree of insulin resistance and beta-cells apoptosis (Pick et al., 1998; Farilla et al., 2002).”
BackgroundSelf-citationMiao, X., Gu, Z., Liu, P., Hu, Y., Li, L., Gong, Y., Shu, H., Liu, Y., & Li, C. (2012) · Peptides · doi:10.1016/j.peptides.2012.10.006 · Cited by 115
Stem/Progenitor Cell Sources of Insulin-Producing Cells for the Treatment of Diabetes
Lock, L. T., & Tzanakakis, E. S. (2007) · Tissue Engineering · doi:10.1089/ten.2007.0047 · Cited by 98
Hui, H., Zhao, X., & Perfetti, R. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.553 · Cited by 97
“1[7–36 amide] and GLP-1 [7–37] have been shown to”
BackgroundSelf-citationFaradji, R. N., Tharavanij, T., Messinger, S., Froud, T., Pileggi, A., Monroy, K., Mineo, D., Baidal, D. A., Cure, P., Ponte, G., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e31818fe448 · Cited by 97
Glucagon-like peptide 1 agonists and the development and growth of pancreatic β-cells
List, J. F., & Habener, J. F. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00007.2004 · Cited by 94
“In the ZDF rat model, GLP-1 stimulates increased replication of insulin-negative cells both within islets and in the exocrine pancreatic parenchyma (22).”
BackgroundInfluentialMukai, E., Fujimoto, S., Sato, H., Oneyama, C., Kominato, R., Sato, Y., Sasaki, M., Nishi, Y., Okada, M., & Inagaki, N. (2011) · Diabetes · doi:10.2337/db10-0021 · Cited by 92
“Previous studies have shown that GLP-1 also has beneficial long-term effects on diabetic -cells, including induction of -cell proliferation (16,17), enhanced resistance to apoptosis (17,18), and amelioration of endoplasmic reticulum stress (19).”
BackgroundTatarkiewicz, K., Smith, P. A., Sablan, E. J., Polizzi, C. J., Aumann, D. E., Villescaz, C., Hargrove, D. M., Gedulin, B. R., Lu, M. G. W., Adams, L., et al. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00479.2010 · Cited by 91
“Moreover, GLP-1 has been observed to improve -cell mass by augmenting -cell survival and proliferation in rodents (7, 19, 42).”
BackgroundJimenez‐Solem, E., Rasmussen, M. H., Christensen, M., & Knop, F. K. (2010) · PubMed · Cited by 89
Hansen, A. M. K., Bödvarsdóttir, T., Nordestgaard, D. N. E., Heller, R. S., Gotfredsen, C. F., Maedler, K., Fels, J. J., Holst, J. J., & Karlsen, A. E. (2011) · Diabetologia · doi:10.1007/s00125-011-2080-1 · Cited by 89
“Several in vitro [3, 4] and rodent in vivo studies [5–7] have demonstrated antiapoptotic and proliferative effects of GLP-1 on pancreatic beta cells.”
BackgroundProtection of pancreatic beta-cells: Is it feasible?
Bonora, E. (2007) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.05.004 · Cited by 106
Glucagon and Glucagon-Like Peptide Receptors as Drug Targets
Estall, J., & Drucker, D. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206776873671 · Cited by 88
“More recently, considerable experimental evidence indicates that activation of GLP-1R signaling can also protect β−cells from programmed cell death (apoptosis) and stimulate β−cell proliferation in cultured rodent and human islets and in rodent models of diabetes [95-99].”
BackgroundIslet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment
King, A., Hollister‐Lock, J., Xu, G., Bonner‐Weir, S., & Weir, G. C. (2005) · Diabetologia · doi:10.1007/s00125-005-1922-0 · Cited by 90
“Moreover, GLP-1 and exendin-4 have been reported to reduce beta cell apoptosis [7, 8].”
BackgroundSheffield, C. A., Kane, M. P., Busch, R., Bakst, G., Abelseth, J. M., & Hamilton, R. A. (2008) · Endocrine Practice · doi:10.4158/ep.14.3.285 · Cited by 87
β-cell apoptosis in type 2 diabetes: quantitative and functional consequences
Lupi, R., & Prato, S. D. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73396-2 · Cited by 105
“An ability to stimulate β-cell replication in vitro followed by up regulated expression of the transcription factor PDX-1 (which is involved in pancreatic development, islet cell function, regulation of insulin gene expression, and the increase of βcell mass in animal models) has also been ascribed to GLP1 [87-89].”
BackgroundRecent and emerging anti‐diabetes targets
Mohler, M. L., He, Y., Wu, Z., Hwang, D., & Miller, D. D. (2008) · Medicinal Research Reviews · doi:10.1002/med.20142 · Cited by 93
“A benzamide lacking the carboxylic acid (70)(182) (Fig.”
BackgroundPortha, B., Tourrel-Cuzin, C., & Movassat, J. (2011) · Experimental Diabetes Research · doi:10.1155/2011/376509 · Cited by 85
“Ex-4 treatment of Lepdb/Lepdb mice decreases activation of caspase-3 and prevents beta-cell apoptosis through PKB and MAPK [85] and infusion with GLP-1 drastically reduced the number of apoptotic beta cells in islets of Zucker diabetic rats [65].”
BackgroundMaida, A., Hansotia, T., Longuet, C., Seino, Y., & Drucker, D. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.09.004 · Cited by 96
ZHAO, X., LIU, G., SHEN, H., GAO, B., LI, X., FU, J., ZHOU, J., & JI, Q. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.2052 · Cited by 83
“It has been shown to exert various beneficial effects on pancreatic β -cells, such as the enhancement of glucose-dependent insulin secretion (27), the acceleration of β -cell proliferation and the inhibition of β -cell apoptosis (28).”
Pabreja, K., Mohd, M. A., Koole, C., Wootten, D., & Furness, S. G. B. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12313 · Cited by 84
“Activation of the GLP-1R on pancreatic β-islets results in potentiation of glucose-dependent insulin secretion as well as improvements in beta cell function and mass in animal models (Xu et al., 1999; Perfetti et al., 2000; Stoffers et al., 2000; Tourrel et al., 2001; Farilla et al., 2002; Rolin et al., 2002; Wang and…”
Background
Metadata
- Authors
- Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R.
- Affiliations
- Cedars-Sinai Medical Center (US)
- University of California, Los Angeles (US)
- Corresponding author
- Perfetti, Riccardo
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2002-11-01
- Volume
- 143
- Issue
- 11
- Pages
- 4397-4408
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2063693981
- Cited by
- 502
- References
- 20
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 5 · 2023: 10 · 2022: 5 · 2021: 17 · 2020: 12 · 2019: 18 · 2018: 12 · 2017: 16 · 2016: 18 · 2015: 25 · 2014: 32 · 2013: 33 · 2012: 33
- FWCI
- 17.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Federation for Aging Research
- Cedars-Sinai Medical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- glucagon-like peptide-1, islet cell proliferation, beta-cell apoptosis, type 2 diabetes, insulin secretion, glucose tolerance, caspase-3, Ki-67, exocrine pancreas, pancreatic islets, nuclear fragmentation
- MeSH terms
- Insulin Secretion, Animals, Blood Glucose, Cell Division, Diabetes Mellitus, Glucagon, Insulin, Islets of Langerhans, Kinetics, Male, Peptide Fragments, Protein Precursors, Rats, Zucker, Apoptosis, Ki-67 Antigen, Caspases, In Situ Nick-End Labeling, Rats, Glucagon-Like Peptide 1, Caspase 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.